Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

157.54 +0.34 (+0.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
Via Benzinga
This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
A Glimpse of Ascendis Pharma's Earnings Potential
Via Benzinga
Why ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) could fit Mark Minervini’s high-growth criteria
A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing? 
Via Chartmill
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
Via Benzinga
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
Via Benzinga
Earnings Scheduled For February 12, 2025
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Via Benzinga
Does ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) show the characteristics of a Minervini super stock?
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND). 
Via Chartmill
Looking Into Ascendis Pharma's Recent Short Interest
Via Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
Via Benzinga
Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) a Minervini-style stock?
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND). 
Via Chartmill
Why Is BioMarin Stock Trading Higher On Thursday?
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results. 
Via Benzinga
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target. 
Via Benzinga
Looking Into Ascendis Pharma's Recent Short Interest
Via Benzinga
Peering Into Ascendis Pharma's Recent Short Interest
Via Benzinga
(ASND) - Analyzing Ascendis Pharma's Short Interest
Via Benzinga
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp. 
Via Stocktwits
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon? 
Via MarketBeat
A Glimpse of Ascendis Pharma's Earnings Potential
Via Benzinga
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date. 
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Via Benzinga
Looking Into Ascendis Pharma's Recent Short Interest
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments. 
Via Benzinga
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.